cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Xenon Pharmaceuticals Inc
4 own
20 watching
Current Price
$38.85
$-0.76
(-1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,429.78M
52-Week High
52-Week High
41.39
52-Week Low
52-Week Low
24.94
Average Volume
Average Volume
0.23M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,429.78M
icon52-Week High41.39
icon52-Week Low24.94
iconAverage Volume0.23M
iconDividend Yield--
iconP/E Ratio--
What does the Xenon Pharmaceuticals Inc do?
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company uses Extreme Genetics, a core enabling discovery platform for the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels, known as channelopathies. It offers Glybera, a gene therapy product for the treatment of patients with orphan lipid disorder lipoprotein lipase deficiency. The company is also developing TV-45070, which is in Phase IIb clinical trials in patients with post-herpetic neuralgia; GDC-0276 and GDC-0310 that completed Phase I clinical trials for the treatment of pain; and XEN801, a stearoyl Co-A desaturase-1 inhibitor that is in Phase II clinical trials in patients with moderate to severe facial acne. Its preclinical product candidate includes XEN901, a selective Nav1.6 sodium channel inhibitor for the treatment of childhood epilepsy disorders. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd.; Genentech, Inc.; uniQure Biopharma B.V.; and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Read More
How much money does Xenon Pharmaceuticals Inc make?
News & Events about Xenon Pharmaceuticals Inc.
Ticker Report
6days ago
Xenon Pharmaceuticals (NASDAQ:XENE Get Rating) had its price objective lifted by Royal Bank of Canada from $49.00 to $51.00 in a research report report published on Tuesday , Benzinga reports. Royal Bank of Canada currently has an outperform rating on the biopharmaceutical companys ...
Globe Newswire
1month ago
XEN1101 Phase 3 Epilepsy Program Ongoing in Focal Onset Seizures and Recently Initiated in Primary Generalized Tonic Clonic Seizures Strong financial position expected to fully support XEN1101 Phase 3 program development and cash runway into 2026 BURNABY, British Columbia, Jan. 09, 2023 (GLOBE ...
Zolmax
1month ago
Xenon Pharmaceuticals Inc. (NASDAQ:XENE Get Rating) was the target of unusually large options trading activity on Wednesday. Traders bought 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the typical volume of 165 put options. Analyst Upgrades and ...
Globe Newswire
2 months ago
Company Presents Additional Positive Data from Open Label Extension of Phase 2b X-TOLE Clinical Trial for Focal Onset Seizures XEN1101 Phase 3 Program to be Showcased at Scientific Exhibit Taking Place on Sunday, December 4, 2022 BURNABY, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Xenon ...
Globe Newswire
3 months ago
BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. Ms. DiFabio will provide ...
Frequently Asked Questions
Frequently Asked Questions
What is Xenon Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Xenon Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Xenon Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Xenon Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Xenon Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Xenon Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Xenon Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Xenon Pharmaceuticals Inc?
plus_minus_icon
What percentage is Xenon Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Xenon Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$38.85
$-0.76
(-1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$64.96
$-0.99 (-1.50 %)
Ardelyx Inc
Ardelyx Inc
$3.28
$-0.07 (-2.09 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$3.09
$0.20 (6.92 %)
Phibro Animal Health Corp
Phibro Animal Health Corp
$15.90
$-0.15 (-0.93 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$64.96
$-0.99 (-1.50 %)
Ardelyx Inc
Ardelyx Inc
$3.28
$-0.07 (-2.09 %)
Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc.
$3.09
$0.20 (6.92 %)
Phibro Animal Health Corp
Phibro Animal Health Corp
$15.90
$-0.15 (-0.93 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00